Background: An inverse relation between Helicobacter pylori infection and asthma has been shown in epidemiological studies. Infection with H. pylori, or application of an extract of it before or after sensitization, inhibits allergic airway disease in mice. Objectives: The aim of this study was to investigate the effect of an extract of H. pylori on allergic airway disease induced by repeated allergen exposure in mice that were sensitized and challenged prior to extract application. Method: C57BL/6 mice were intranasally (i.n.) sensitized and challenged with house dust mite (HDM). After a minimum of 4 weeks, mice received the H. pylori extract intraperitoneally and were rechallenged i.n. with HDM. Allergen-specific antibodies were measured by ELISA. Cells present in the bronchoalveolar lavage fluid and dendritic cell (DC) subsets in the lung tissue were analyzed by flow cytometry. Tissue inflammation and goblet cell hyperplasia were assessed by histology. Cells of the mediastinal lymph node (mLN) were isolated and in vitro restimulated with HDM or H. pylori extract.
Introduction
Asthma is a common syndrome of increasing prevalence [1] . Current treatment of patients with asthma consists of anti-inflammatory drugs such as inhaled corticosteroids, often in combination with bronchodilators. All available treatment options are symptomatic, and symptoms usually return when treatment is paused or stopped. Also, disease-modifying effects by novel treatments with monoclonal antibodies against IgE [2, 3] or IL-5 [4] in patients with severe asthma have not been shown. Furthermore, 5-10% of patients do not respond to high-dose therapies (a combination of high-dose inhaled/oral corticosteroids and β2-adrenoceptor agonists) [5] and the number of novel drugs for asthma that have reached the market is small considering the efforts made and costs accrued [6] . Therefore, further efforts are needed to develop treatments that modify the course of the disease.
Colonization of the stomach with the bacterium H. pylori has been shown to protect against the development of asthma in many epidemiological studies [7, 8] . Experimental infection with Helicobacter pylori or treatment with an H. pylori extract before sensitization to allergens inhibited allergic airway inflammation (AAI) in murine models [9] [10] [11] . Protection was dependent on the induction of tolerogenic dendritic cells (DCs). We recently showed that AAI was also reduced when the extract was applied at a later point of induction of AAI, i.e., in mice that had been sensitized (but not yet challenged) prior to treatment with the H. pylori extract [12] . Antigen processing by DCs was reduced in vivo and in vitro after exposure to the extract. However, the model of acute airway disease that we have investigated so far has the drawback that treatment is administered before airway inflammation has developed. In patients with allergic asthma, symptoms and airway inflammation repeatedly occur after allergen exposure [1] . Therefore, we set out to test a potential treatment in a model with repeated allergen exposures to assess the potential therapeutic effect.
We hypothesized that an extract of H. pylori would reduce allergic airway disease induced by repeated allergen exposure when applied to mice that were previously sensitized and challenged. To this end, mice were sensitized and challenged prior to a period of rest, treated with the extract, and then rechallenged with the allergen.
Materials and Methods

Animals
Eight-to twelve-week-old female C57BL/6 mice were purchased from Charles River ('s-Hertogenbosch, The Netherlands). The animals had free access to food and water, and were housed in individually ventilated cages under specific pathogen-free conditions. Experiments were performed at the animal facilities of the Leiden University Medical Center in Leiden, The Netherlands. The Ethics Committee for Animal Experimentation of the University of Leiden approved the experiments (Dieren Experimentele Commissie, DEC, 12246), which were conducted under strict governmental and international guidelines in accordance with EU Directive 2010/63/EU.
Experimental Protocols for AAI Induced by Rechallenge and Intervention
To induce AAI, mice were intranasally (i.n.) sensitized with 1 μg of house dust mite (HDM; Greer, Lenoir, NC, USA) in 50 μL of PBS, and challenged by five i.n. applications of 10 μg HDM in 50 μL of PBS 1 week later (Fig. 1) . After a period of rest of at least 4 weeks, the mice were rechallenged by three i.n. applications of 10 μg HDM in 50 μL of PBS. As a control, some mice that were sensitized and challenged with HDM received PBS at the time that the other mice were rechallenged with HDM. All i.n. administrations were performed under isoflurane anesthesia (3%, 0.8 L/min). H. pylori extract (200 μg) in 100 μL of PBS was applied intraperitoneally (i.p.) 5 and 3 days before the rechallenge and was continued daily from 1 day before the rechallenge to 1 day thereafter. As a control, the remaining mice received 100 μL of PBS i.p. On days in which the mice were both treated with the extract and were rechallenged with HDM, the extract was administered 1 h before HDM exposure. Mice were analyzed 2 days after the final HDM exposure. Mice were euthanized with an overdose of sodium pentobarbital (Euthasol, AST Farma, Oudewater, The Netherlands). Analyses of the blood, bronchoalveolar lavage (BAL) fluid, and lung tissue were performed as previously published [12] . Blood was collected from the vena cava. After three lavages of the lungs with 1 mL of PBS that was applied via a tracheal canula, the lungs were perfused with PBS via the heart. The mediastinal lymph node (mLN) was removed and collected in PBS. For flow cytometry analysis, the left lobe of the lungs was collected in PBS. To study the histology, the right lobes were inflated with 3.9% (v/v) formaldehyde (Sigma-Aldrich) in PBS after ligature.
Preparation of H. pylori Extract
The H. pylori extract was prepared as previously published [12] . In short, the H. pylori pre-mouse SS1 strain (PMSS1) was cultured on solid agar plates (bioMérieux Benelux B.V., Zaltbommel, The Netherlands) under microaerophilic conditions (6% O 2 , 7.1% CO 2 , 7.1% H 2 , and 79.7% N 2 ; Anoxomat, Mart Microbiology, Drachten, The Netherlands). After testing of the production of a specific combination of enzymes to assure that the culture contained H. pylori, the bacteria were transferred to BBL broth with 10% FCS (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and were further cultured under microaerophilic conditions at 37 ° C in a shaking incubator (New Brunswick Scientific Europe B.V., Nijmegen, The Netherlands) at 185 rpm. After checking the purity by Gram-staining of the pellets, the bacteria were pooled, washed in PBS, freeze-thawed in nitrogen, and subjected to a pressure of 3,000 bar in a French pressure cell press (Stansted Fluid Power, Cell Pressure Homogenizer, Harlow, UK). The supernatant was filtered through a 0.2-µm filter and the protein content was determined using bicinchoninic acid (BCA protein Kit Pierce, Thermo Fisher Scientific). The concentration of the extract was adjusted using PBS.
Anti-HDM IgE and IgG1
Serum was obtained by centrifugation of the collected blood, and was diluted in 1% (w/v) BSA/PBS (Sigma-Aldrich). NUNC Maxisorb plates (Sigma-Aldrich) were coated with 50 µg/mL of HDM in 0.1 M sodium-carbonate buffer pH 9.6 and non-specific binding sites were blocked with 1% BSA/PBS. After incubation with the samples, HDM-specific antibodies were detected using biotin-labelled anti-mouse IgE (clone 23G3; Southern Biotech, Birmingham, AL, USA) or biotin-labelled anti-mouse IgG1 (clone A85-1; BD Pharmingen, Becton Dickinson B.V., Breda, The Netherlands). Streptavidin coupled to HRP (Sanquin, Amsterdam, The Netherlands) and TMB (3,3′,5,5′-tetramethylbenzidine) were added to quantify the antibody binding. A Bio-Rad iMark microplate reader was used for measurement of the ODs at 450 nm.
Flow Cytometry
Quantification of cells in the BAL fluid was performed using Türk's solution (Merck, Schiphol-Rijk, The Netherlands). A single cell suspension was obtained from lung tissue by dissecting the tissue into small pieces. Collagenase/DNAse (Collagenase Type I of Clostridium histolyticum; Calbiochem, San Diego, CA, USA; DNAse I; Sigma-Aldrich) was added for 45 min at 37 ° C. The mixture was filtered through a 70-µm cell strainer (BD Falcon, Becton Dickinson). After the lysis of red blood cells, the cells were counted on a Countess automatic cell counter (Invitrogen, Thermo Fisher Scientific). The mLN was filtered through a 70-µm cell strainer (BD Falcon, Becton Dickinson) and the single cell suspension was counted using trypan blue. Cells of the BAL fluid, lung tissue, and mLN were labelled with the live/dead stain Aqua (Invitrogen, Thermo Fisher Scientific). Cells of the BAL fluid and lung tissue were fixed with 2% formaldehyde (Merck) in PBS. The antibodies used for flow cytometry and gating strategies for analysis have been previously published [12] . Treg analysis of cells in the mLN was performed using the eBioscience Foxp3/Transcription factor staining buffer set (Invitrogen). The following antibodies were used: CD4-FITC (GK1.5, eBioscience, Thermo Fisher Scientific), CD25-PerCP-Cy5. 
Histology
Paraffin sections of 4 μm were obtained from formaldehydeinflated tissue (fixed for 48 h at room temperature). Peribronchial inflammation was scored on a 5-point scale (0-4) after staining with hematoxylin and eosin (HE, both Klinipath, Duiven, The Netherlands). In this semiquantitative method, 0 indicates that no inflammation around airways or vessels was detected; 1 indicates that there were some infiltrates of maximum two layers thick; 2 indicates that infiltrates of up to two layers were found at the majority of airways and vessels, and occasionally thicker layers were found; 3 indicates that the majority of airways and vessels were inflamed with more than two layers of cells, but occasionally thinner layers were present; and 4 indicates that all airways and vessels were surrounded by thick layers of inflammatory cells. The analysis was performed by two separate investigators in a blinded fashion. Goblet cell hyperplasia was assessed in tissue stained with Alcian blue and periodic acid-Schiff (PAS) dyes (both from SigmaAldrich). Digital images were taken at 10× magnification on an Olympus BX41 microscope (Olympus Nederland B.V., Leiderdorp, The Netherlands). Epithelial regions were selected and the fraction of positively stained area corresponding to mucin density was calculated using ImageJ software 1.46r (National Institute of Health, Bethesda, MD, USA). Cytometric Bead Array The mLN was removed from mice that underwent H. pylori or control treatment for AAI. The mLN was mashed through a 70-µm falcon cell strainer and the strainer was washed with Dulbecco's PBS (Gibco, Thermo Fisher Scientific). After centrifugation, 200,000 cells were cultured in 10% FCS RPMI supplemented with 100 U/mL penicillin and 100 U/mL streptomycin (Lonza), and stimulated with (10 µg/mL) HMD or (10 µg/mL) H. pylori extract for 4 days. Supernatant was collected and subjected to cytometric bead array (BD Biosciences) according to the manufacturer's protocol.
Statistical Analysis
GraphPad PRISM 7.02 (GraphPad Software Inc., La Jolla, CA, USA) was used to create graphs and to perform statistical analysis. Data are shown as means ± standard error of the mean (SEM). Differences were considered significantly different at p values < 0.05 examined by ANOVA and the Dunnett multiple comparisons analysis. For analysis of cytokine production after stimulation of mLN, the two-stage step-up method of Benjamini, Krieger, and Yekutieli was applied to correct for multiple comparisons when performing multiple t tests.
Results
Mice were initially sensitized with HDM in week 1 and then challenged during week 2. Following a rest period of at least 4 weeks, the mice were rechallenged with HDM. The mice were i.p. treated with an extract of H. pylori prior to a rechallenge (see the experimental set up Fig. 1 ). HDM-specific IgE was significantly induced following rechallenge with HDM compared to exposure to PBS (Fig. 2a) . Treatment with H. pylori extract resulted in a significant reduction of anti-HDM IgE levels in serum. However, mice that were rechallenged and treated with the H. pylori extract did have significantly higher anti-HDM IgE levels compared to mice that received PBS at the moment of rechallenge (p = 0.001). No difference in HDM-specific IgG1 levels could be detected between mice rechallenged with HDM compared to mice that received PBS at the rechallenge, and HDM-specific IgG1 was not affected by the treatment (Fig. 2b) .
Control mice that received PBS only instead of HDM at rechallenge exhibited low total cell counts and low numbers of eosinophils in BAL fluid, showing that inflammation induced by the first challenge of sensitized mice was mostly resolved after the period of rest (Fig. 3a,  b) . Rechallenge with HDM led to a significant increase in the number of total cells in the BAL fluid, which was not affected by treatment with H. pylori extract. When assessing differential cell counts in BAL fluid, relative and absolute numbers of eosinophils in the BAL fluid were increased following rechallenge with HDM (Fig. 3b, c) . Treatment with H. pylori extract resulted only in a small, but significant, reduction in the percentage of eosinophils (Fig. 3c) . Absolute numbers of eosinophils in BAL fluid were not statistically significantly reduced (Fig. 3b) .
In the lung tissue, inflammation was low following i.n. exposure to PBS at the time when other mice were rechallenged with HDM (Fig. 4a, b) as only few infiltrates around the airways and blood vessels of the lung were found. Rechallenge with HDM resulted in a significant increase in inflammation as assessed by HE staining of the lung tissue. Overall inflammation of the lung tissue was not inhibited by treatment with the extract. No mucus production was detected in mice after rechallenge with PBS (Fig. 4a, c) , but HDM rechallenge resulted in an increase in mucus production. Mice treated with H. pylori extract showed a significant reduction in mucus production. We have reported previously that treatment with the H. pylori extract between sensitization and challenge led to a reduction in the number of DCs in the lung, a shift in the subtypes of DCs, and a reduced capacity to process antigen [12] . In the therapeutic model, the number of DCs in the lungs was also reduced, however we did not detect a shift in the ratio of CD11b + proinflammatory to CD103 + anti-inflammatory DCs, or in the ratio of proinflammatory monocyte-derived CD11b + CD64 + DCs to conventional CD11b + CD64 -DCs (Fig. 5) .
The mLN is the lymph node that drains the lungs, and it was shown to also be involved in drainage after i.p. injection of ovalbumin in alum [13] . Therefore, we were interested in mLN responses to the allergen and the extract. When cells of the mLN were restimulated with HDM, the cells of mice that were in vivo treated with H. pylori extract prior to the rechallenge produced significantly more IL-10 and IL-17 than cells of mice rechallenged with HDM without being treated with the extract (Fig. 6a) . After in vitro restimulation with H. pylori extract, cells of mice that were in vivo treated with the extract produced more interferon gamma (IFNγ) than cells of mice that did not receive the extract in vivo. The percentage of Foxp3 + Tregs in the mLN was decreased after treatment of the mice with H. pylori extract (Fig. 6b) .
Discussion
Previous studies have shown that the induction of AAI is reduced in mice infected with H. pylori or treated with an H. pylori extract prior to the induction of allergy [9] [10] [11] . Also, the application of an extract of the bacterium after sensitization results in amelioration of the development of the disease [12] . In the present study, we investigated a possible therapeutic effect of treatment directly before a rechallenge in previously sensitized and challenged animals. The results show that intervention at rechallenge leads to a reduction of select, but not all features of the disease. Indeed, HDM-specific IgE in serum was significantly reduced in mice treated with the H. pylori extract. In the lung tissue, the number of DCs and extent of goblet cell hyperplasia were significantly reduced. Cells from the mLN of mice treated with the H. pylori extract that were restimulated with HDM produced significantly more IL-10 than mLN cells of mice that were not treated with the extract. To mimic asthma in vivo, we used a rechallenge model of AAI. This is a relevant model, as patients with allergic asthma can show increased inflammation and symptoms following allergen exposure, but can also be asymptomatic. Still, the residual inflammation in patients that do not experience any symptoms can contribute to a next attack. It was previously shown that inflammation was mostly resolved 6 weeks after sensitization and challenge of mice with OVA, but that a secondary challenge alone induced inflammation in these mice [14] , indicating that prior allergic airway disease contributes to the development of AAI after a second challenge.
Whereas most attempts to inhibit AAI with micro-organism-based approaches have been described in preventive models, some studies [12, 15] showed that AAI can be inhibited when micro-organism preparations are applied to sensitized mice. Fewer studies report on successfully inhibiting AAI when applying micro-organism preparations after a prior sensitization and challenge [15, 16] . Thorburn et al. [15] showed that components of Streptococcus pneumoniae applied during established disease inhibited allergic airway disease by the induction of Tregs that inhibited natural killer T-cells. Lagranderie et al. [16] demonstrated inhibition of AAI by a freeze-dried preparation of Mycobacterium bovis BCG applied after the induction of established disease, which was associated with the induction of the immunosuppressive cytokine IL-10. The persistence of the observed treatment effects requires further analysis. Navarro et al. [17] showed that a mix of bacterial extracts (Broncho-Vaxom, used for recurrent respiratory infections) could inhibit AAI when applied orally from 1 day before the sensitization until the challenge. When mice were rechallenged 3 weeks later, treatment was no longer effective, indicating that protection was short lived. Others showed that treatment that was started before the sensitization was still effective when mice were challenged 30 days after infection with Escherichia coli [18] .
In our experience, treatment at a later stage of the disease (before a second challenge) affected goblet cell hyperplasia, but had less effect on inflammation compared to treatment before the first challenge [12] . To reduce inflammation caused by a rechallenge, more frequent injections with H. pylori extract for a longer period of time might be required.
The largest effect of treatment was on goblet cell hyperplasia, total amount of DCs in the lung tissue, antigenspecific IgE in serum, and IL-10 in the mLN. H. pylori extract affects antigen processing by DCs [12] . It is possible that the extract also induced IL-10 production by DCs, or that T cells that are skewed by the DCs produce IL-10. This is supported by the increased production of IL-10 after restimulation with HDM of cells of the mLN in mice treated with the extract. IL-10 has a central role in the control of asthma, and is known to inhibit many different cells and their functions in allergic disease, including mast cells [19] [20] [21] . Production of IL-10 may have led to reduced goblet cell hyperplasia, either by an effect on mast cells, or by another mechanism. Another possibility is that goblet cell hyperplasia is reduced as a consequence of reduced IL-13 production. The role of IL-13 in mucus hypersecretion and induction of airway hyperresponsiveness in mice has been well described and blocking IL-13 mainly reduces these features with less effect on airway inflammation [22, 23] . IL-13 is known to induce goblet cell hyperplasia directly in mouse epithelial cells [22] . The role of IL-13 in mucus hypersecretion is furthermore supported by in vitro studies with cultured human airway epithelial cells, showing the ability of IL-13 to induce goblet cell hyperplasia [24, 25] . Two ways that treatment with the extract could lead to reduced IL-13 production is that the extract affects Th2 cell skewing by DCs, or that the reduction in IgE leads to reduced IL-13 release by mast cells [26] . Although we did not observe a reduction in production of Th2 cytokines by cells in the mLN after restimulation with the allergen in mice treated with the extract, we cannot formally exclude that IL-13 is reduced in BAL fluid or lung tissue. Applying the extract i.n. with the intention to target the epithelium directly proved to be less successful in inhibiting AAI than i.p. injection in the more acute models [Y. van Wijck; unpubl. observations].
In clinical research it has been recognized that different phenotypes in asthma exist, which are susceptible to different treatment approaches. Therefore, modelling asthma also needs to consider various models for different phenotypes [6] . The most widely investigated asthma phenotype in such animal models is allergic, eosinophilic asthma. The current results show that certain characteristics of AAI and airway remodelling can also be inhibited in a more chronic model of the disease by using an extract of H. pylori.
To conclude, treatment of AAI with an extract of H. pylori at the time of a rechallenge inhibited goblet cell hyperplasia and selected inflammatory features of the disease. Therefore, this extract or its active components might be meaningful as a new therapeutic option for patients with asthma.
